参考文献/References:
[1]Greten FR,Grivennikov SI.Inflammation and Cancer:Triggers,Mechanisms,and Consequences[J].Immunity,2019,51(1):27-41. [2]Cakici M,Cetin M,Dogan A,et al.Pas de Deux:Control of Anti-tumor Immunity by Cancer-Associated Inflammation-ScienceDirect[J].Immunity,2014,51(1):15-26. [3]Salman T,Kazaz SN,Varol U,et al.Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio for Patients with Neuroendocrine Tumors:An Izmir Oncology Group Study[J].Chemotherapy,2016,61(6):281-286. [4]Kim H,Sang MR,Ji HY,et al.The neutrophil-to-lymphocyte ratio prechemotherapy and postchemotherapy as a prognostic marker in metastatic gastric cancer[J].The Korean Journal of Internal Medicine,2018,33(5):990-999. [5]Luo H,Hong G,Cui Y,et al.Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience[J].Journal of Cancer,2018,9(1):182-188. [6]Choi Y,Jin WK,Nam KH,et al.Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer[J].Gastric Cancer,2016,27(4):1-10. [7]Krenn-Pilko S,Langsenlehner U,Stojakovic T,et al.The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients[J].Tumor Biology,2016,37(1):361-368. [8]Xue LB,Liu YH,Zhang B,et al.Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy:Meta-analysis[J].Medicine,2019(98):e13842. [9]Mantovani A,Allavena P,Sica A,et al.Cancer-related inflammation[J].Nature,2008,454(7203):436-444. [10]Diakos CI,Charles KA,Mcmillan DC,et al.Cancer-related inflammation and treatment effectiveness[J].Lancet Oncology,2014,15(11):e493-e503. [11]Grivennikov SI,Greten FR,Karin M.Immunity,Inflammation,and Cancer[J].Cell,2010,140(6):883-899. [12]Oshima M,Okano K,Suto H,et al.Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer[J].BMC Gastroenterology,2020,20(1):423. [13]Shao Y,Wu B,Jia W,et al.Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma:a systematic review and meta-analysis[J].BMC Urology,2020,20(1):90. [14]Donate-Moreno MJ,Ls B,Msm A,et al.Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer[J].Actas Urologicas Espanolas,2020,44(10):692-700. [15]Wang Q,Zhu SR,Huang XP,et al.Prognostic value of systemic immune-inflammation index in patients with urinary system cancers:a meta-analysis[J].Eur Rev Med Pharmacol Sci,2021,25(3):1302-1310. [16]Yapar A,Tokgz MA,Yapar D,et al.Diagnostic and prognostic role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio,and lymphocyte/monocyte ratio in patients with osteosarcoma[J].Joint Diseases and Related Surgery,2021,32(2):i-viii. [17]Guo L,Wang Q,Chen K,et al.Prognostic Value of Combination of Inflammatory and Tumor Markers in Resectable Gastric Cancer[J].Journal of Gastrointestinal Surgery,2021. [18]Uludag SS,Sanli AN,Zengin AK,et al.Systemic Inflammatory Biomarkers as Surrogate Markers for Stage in Colon Cancer[J].The American Surgeon,2021:3134821995059. [19]Xia LJ,Li W,Zhai JC,et al.Significance of neutrophil-to-lymphocyte ratio,platelet-to-lymphocyte ratio,lymphocyte-to-monocyte ratio and prognostic nutritional index for predicting clinical outcomes in T1-2 rectal cancer[J].BMC Cancer,2020,20(1):208. [20]Zeng YC,Feng C,Rui X,et al.Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy[J].Japanese Journal of Clinical Oncology,2016,46(2):126-131. [21]Ha H,Nam AR,Bang JH,et al.Soluble programmed death-ligand 1(sPDL1)and neutrophil-to-lymphocyte ratio(NLR)predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy[J].Oncotarget,2016,7(47):76604-76612. [22]Sebastian NT,Raj R,Prasad R,et al.Association of Pre- and Posttreatment Neutrophil-Lymphocyte Ratio With Recurrence and Mortality in Locally Advanced Non-Small Cell Lung Cancer[J].Frontiers in Oncology,2020(10):598873. [23]Zhao Z,Zhao X,Lu J,et al.Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer:a meta-analysis of retrospective studies[J].Archives of Gynecology&Obstetrics,2018,297(4):849-857. [24]Gago-Dominguez M,Matabuena M,Redondo CM,et al.Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions[J].Scientific Reports,2020,10(1):13203. [25]Templeton AJ,Ace O,Mcnamara MG,et al.Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors:a systematic review and meta-analysis[J].Breast Cancer Research,2017,19(1):2. [26]Eren T,Karacin C,Ucar G,et al.Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients[J].Medicine,2020,99(22):e20346.
相似文献/References:
[1]袁东方,张刚刚.恶性肿瘤病历主要诊断选择思路分析[J].医学信息,2018,31(07):28.[doi:10.3969/j.issn.1006-1959.2018.07.010]
YUAN Dong-fang,ZHANG Gang-gang.Analysis of Main Diagnostic Options for Malignant Tumor Records[J].Medical Information,2018,31(08):28.[doi:10.3969/j.issn.1006-1959.2018.07.010]
[2]陶碧君,刘建德,王玉洲.LncRNA FOXD3-AS1在恶性肿瘤中的表达、功能及作用机制[J].医学信息,2022,35(10):51.[doi:10.3969/j.issn.1006-1959.2022.10.012]
TAO Bi-jun,LIU Jian-de,WANG Yu-zhou.Expression, Function and Mechanism of LncRNA FOXD3-AS1 in Malignant Tumors[J].Medical Information,2022,35(08):51.[doi:10.3969/j.issn.1006-1959.2022.10.012]
[3]陈学敏,彭 琼.中性粒细胞与淋巴细胞比值联合癌胚抗原对结直肠癌早期诊断的研究[J].医学信息,2019,32(02):75.[doi:10.3969/j.issn.1006-1959.2019.02.022]
CHEN Xue-min,PENG Qiong.Early Diagnosis of Colorectal Cancer by Neutrophil-lymphocyte Ratio Combined with Carcinoembryonic Antigen[J].Medical Information,2019,32(08):75.[doi:10.3969/j.issn.1006-1959.2019.02.022]
[4]张国锐,贾 林,赵 丹,等.老年维持血液透析患者恶性肿瘤发病的相关因素分析[J].医学信息,2022,35(10):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
ZHANG Guo-rui,JIA Lin,ZHAO Dan,et al.Analysis of Related Factors of Malignant Tumor in Elderly Maintenance Hemodialysis Patients[J].Medical Information,2022,35(08):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
[5]郭 磊,王小文,向小勇.中性粒细胞与淋巴细胞比值与肺癌预后关系研究[J].医学信息,2019,32(09):35.[doi:10.3969/j.issn.1006-1959.2019.09.012]
GUO Lei,WANG Xiao-wen,XIANG Xiao-yong.Relationship between Neutrophil-lymphocyte Ratio and Prognosis of Lung Cancer[J].Medical Information,2019,32(08):35.[doi:10.3969/j.issn.1006-1959.2019.09.012]
[6]姜天奇,张洪亮.原发性肝癌的中西医治疗现状[J].医学信息,2019,32(13):35.[doi:10.3969/j.issn.1006-1959.2019.13.012]
JIANG Tian-qi,ZHANG Hong-liang.Current Status of Treatment of Primary Liver Cancer with Traditional Chinese Medicine and
Western Medicine[J].Medical Information,2019,32(08):35.[doi:10.3969/j.issn.1006-1959.2019.13.012]
[7]何 静.上皮性卵巢癌化学治疗的研究[J].医学信息,2019,32(18):24.[doi:10.3969/j.issn.1006-1959.2019.18.009]
HE Jing.Chemotherapy of Epithelial Ovarian Cancer[J].Medical Information,2019,32(08):24.[doi:10.3969/j.issn.1006-1959.2019.18.009]
[8]梁春玲,杨文珊.消化道恶性肿瘤的临床分析[J].医学信息,2019,32(18):124.[doi:10.3969/j.issn.1006-1959.2019.18.041]
LIANG Chun-ling,YANG Wen-shan.Clinical Analysis of Malignant Tumors of the Digestive Tract[J].Medical Information,2019,32(08):124.[doi:10.3969/j.issn.1006-1959.2019.18.041]
[9]陈云娥,李 璠,张子怡,等.营养支持治疗对终末期恶性肿瘤患者临床结局影响的Meta分析[J].医学信息,2019,32(19):63.[doi:10.3969/j.issn.1006-1959.2019.19.019]
CHEN Yun-e,LI Fan,ZHANG Zi-yi,et al.Meta-analysis of Effect of Nutritional Support Therapy on Clinical Outcome of Patients with Terminal-stage Malignant Tumor[J].Medical Information,2019,32(08):63.[doi:10.3969/j.issn.1006-1959.2019.19.019]
[10]杜鑫荣.超声造影在肝实质性肿块诊断及鉴别中的临床价值[J].医学信息,2019,32(19):176.[doi:10.3969/j.issn.1006-1959.2019.19.059]
DU Xin-rong.Clinical Value of Contrast-enhanced Ultrasonography in the Diagnosis and Differential Diagnosis of Liver Mass[J].Medical Information,2019,32(08):176.[doi:10.3969/j.issn.1006-1959.2019.19.059]